MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2025.03.023

Медицинская библиотека · American heart journal · 2025

Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial.

Somsen Yvemarie B O, de Winter Ruben W, Wu Jiawei, Hoek Roel, Sprengers Ralf W, Verouden Niels J, Claessen Bimmer E P M, Kleijn Sebastiaan A, Twisk Jos W R, Henriques José P, Spratt James C, Rissanen Tuomas T, McEntegart Margaret B, Maehara Akiko, Nap Alexander, Knaapen Paul

Протокол клинического исследованияСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Percutaneous coronary intervention (PCI) of chronic total coronary occlusions (CTOs) typically involves extensive drug-eluting stent (DES) implantation. As a result, patients undergoing CTO PCI are exposed to a relatively high risk of in-stent restenosis and target lesion revascularization. While the application of drug-coated balloons (DCBs) may improve patient outcome by reducing stent burden, randomized controlled trials investigating the use of DCB in CTO PCI are lacking.

METHODS

The Co-CTO trial (NCT04881812) is a single-blind, noninferiority randomized controlled trial enrolling 144 patients undergoing CTO PCI. A hybrid strategy (stenting of the CTO body and DCB treatment of adjacent disease) will be compared to a complete stenting strategy. The primary study endpoint is in-segment percentage diameter stenosis at 1 year follow-up determined by intravascular ultrasound. Secondary endpoints include major adverse cardiovascular events (a composite of cardiac death, nonfatal myocardial infarction, and ischemia-driven target lesion revascularization) at 1 year, angiographic outcomes, and cardiac symptoms (Canadian Cardiovascular Society Grading Scale, New York Heart Association Classification of Dyspnea).

CONCLUSION

The Co-CTO trial is the first randomized controlled trial exploring a hybrid strategy (DES + DCB) in patients undergoing CTO PCI.

TRIAL REGISTRATION: Registered at ClinicalTrials.Gov under registration number: NCT04881812 (https://clinicaltrials.gov/study/NCT04881812?cond=cto&intr=drug-coated%20balloon&rank=1).

Для цитирования: Somsen Yvemarie B O, de Winter Ruben W, Wu Jiawei, Hoek Roel, Sprengers Ralf W, Verouden Niels J, Claessen Bimmer E P M, Kleijn Sebastiaan A, Twisk Jos W R, Henriques José P, Spratt James C, Rissanen Tuomas T, McEntegart Margaret B, Maehara Akiko, Nap Alexander, Knaapen Paul. Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial.. American heart journal. 2025. DOI: 10.1016/j.ahj.2025.03.023.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.